| Treatment with migalastat can be considered in patients with FD aged ≥16 years with amenable mutations and persistent microalbuminuria, and/or proteinuria and/or eGFR> 30–90 ml/min/1.73 m2. |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.